The subject of this research report is a tiny development-stage biotechnology concern, which means its common stock is, almost by definition, incredibly volatile. Significantly, too, the dual facts that the company's lead new-drug prospect has only completed Phase 2 clinical testing and could be years from commercial viability inject substantial additional uncertainty and risk. That's not all, the results of the two Phase 2 studies haven't even been released yet. Now that all of the prudent investors have been scared off, we highlight here the reasons why we're recommending the shares of Prana Biotechnology Ltd (NASDAQ: PRAN), even if only as an issue worthy of close monitoring. First, an impressive 40 of 42 patients (95.2%) enrolled in one study...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|